Apretude is a medicine approved by the FDA in 2021 to reduce the risk of contracting HIV through sexual contact, also known as pre-exposure prophylaxis (PrEP). PrEP is used to prevent the transmission ...
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition Approved in the US for use in adults and ...
(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...
Apretude (cabotegravir extended-release injectable suspension) is a prescription drug used to help prevent HIV. Apretude can cause side effects that range from mild to serious. Examples include ...
MONTRÉAL, Feb. 13, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
MONTRÉAL, March 5, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results